LGND · Ligand Pharmaceuticals Inc
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-06 | Ligand Reports Second Quarter 2026 Financial Results |
| 2026-07-23 | Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 |
| 2026-07-14 | Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets |
| 2026-06-25 | Ligand Announces Closing of Convertible Senior Notes Offering |
| 2026-06-23 | Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering |
| 2026-06-22 | Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031 |
| 2026-06-10 | Ligand Announces 2026 Investor Day in New York City |
| 2026-05-27 | Ligand to Participate in June Investor Conferences |
| 2026-05-07 | Ligand Reports First Quarter 2026 Financial Results |
| 2026-05-05 | Ligand to Participate in May Investor Conferences |
| 2026-04-27 | Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator |
| 2026-04-22 | Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-14 | Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS |
| 2026-03-26 | Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team |
| 2026-03-04 | Ligand to Participate in March Investor Conferences |
| 2026-02-26 | Ligand Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-12 |
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Conference Call: (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID 3661098 Webcast: Live and replay webcasts of the call are available here . About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech |
| 2026-02-04 |
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m. Eastern Time. Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer representative. About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that |